MX2022009654A - Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. - Google Patents

Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.

Info

Publication number
MX2022009654A
MX2022009654A MX2022009654A MX2022009654A MX2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A
Authority
MX
Mexico
Prior art keywords
mutation
restricted
hla class
cell receptors
tcr
Prior art date
Application number
MX2022009654A
Other languages
English (en)
Spanish (es)
Inventor
Steven A Rosenberg
Rami Yoseph
Noam Levin
Biman C Paria
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2022009654A publication Critical patent/MX2022009654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
MX2022009654A 2020-02-12 2021-02-12 Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. MX2022009654A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975544P 2020-02-12 2020-02-12
PCT/US2021/017794 WO2021163434A1 (en) 2020-02-12 2021-02-12 Hla class i-restricted t cell receptors against ras with g12d mutation

Publications (1)

Publication Number Publication Date
MX2022009654A true MX2022009654A (es) 2022-10-20

Family

ID=74860472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009654A MX2022009654A (es) 2020-02-12 2021-02-12 Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.

Country Status (16)

Country Link
US (1) US20230080742A1 (https=)
EP (1) EP4103597A1 (https=)
JP (1) JP7832111B2 (https=)
KR (1) KR20220143867A (https=)
CN (1) CN115279784A (https=)
AU (1) AU2021221138A1 (https=)
BR (1) BR112022015888A2 (https=)
CA (1) CA3168015A1 (https=)
CL (1) CL2022002208A1 (https=)
CO (1) CO2022012922A2 (https=)
CU (1) CU20220044A7 (https=)
GB (1) GB2609760B (https=)
IL (1) IL295252A (https=)
MX (1) MX2022009654A (https=)
TW (1) TWI900528B (https=)
WO (1) WO2021163434A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202540156A (zh) * 2020-10-02 2025-10-16 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
EP4673167A1 (en) * 2023-02-27 2026-01-07 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
WO2026057812A1 (en) * 2024-09-12 2026-03-19 Medigene Immunotherapies Gmbh T-cell receptor variant against mkras 7-16 g12d

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2007017201A1 (en) * 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen specific t cells
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
MX384919B (es) 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
EP3720478A1 (en) * 2017-12-04 2020-10-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against mutated ras

Also Published As

Publication number Publication date
CU20220044A7 (es) 2023-06-13
CL2022002208A1 (es) 2023-06-02
CN115279784A (zh) 2022-11-01
CA3168015A1 (en) 2021-08-19
CO2022012922A2 (es) 2022-10-21
GB2609760A (en) 2023-02-15
JP2023528112A (ja) 2023-07-04
TW202140536A (zh) 2021-11-01
GB202211733D0 (en) 2022-09-28
JP7832111B2 (ja) 2026-03-17
WO2021163434A1 (en) 2021-08-19
AU2021221138A1 (en) 2022-09-01
TWI900528B (zh) 2025-10-11
IL295252A (en) 2022-10-01
GB2609760B (en) 2026-02-04
US20230080742A1 (en) 2023-03-16
BR112022015888A2 (pt) 2022-10-11
EP4103597A1 (en) 2022-12-21
WO2021163434A8 (en) 2022-09-01
KR20220143867A (ko) 2022-10-25

Similar Documents

Publication Publication Date Title
MX2022009654A (es) Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
MX2022010157A (es) Receptores de células t restringidos a hla clase ii contra ras con mutación g12v.
MX2024005678A (es) Receptores de celulas t que reconocen p53 mutado.
Spies et al. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer
Buus et al. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
EP3301107B1 (en) Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
WO2022015694A8 (en) Hla class ii–restricted drb t cell receptors against ras with g12d mutation
KR20030084992A (ko) 감소된 면역원성을 갖는 개질 인터페론 베타
Celis et al. Genetic restriction and fine specificity of human T cell clones reactive with rabies virus.
JP2004535173A (ja) 低減された免疫原性を有する修飾されたインターフェロンアルファ
JP2010500037A5 (https=)
WO2024206274A3 (en) T cell receptors targeting y220c or r175h mutation in p53
WO2022051449A3 (en) T cell receptors recognizing r273c or y220c mutations in p53
Schmidt et al. Serological and immunochemical studies of H‐2 allospecificities on K36, a syngeneic tumour of AKR
WO2021262829A3 (en) Hla class i-restricted t cell receptors against cd20
WO2026024602A3 (en) T cell receptors against ras with g12d, g12v, g13d or q61r mutation
Maryanski et al. Structural features of peptides recognized by H-2Kd-restricted T cells
Brackenridge et al. Mapping the epitopes of the Human Leukocyte Antigen E antibodies 3D12 and 4D12
Graham et al. Do antigenic drift residues in influenza hemagglutinins of the H3 subtype qualify as contact sites for MHC class II interaction?
CN111621564B (zh) 一种鉴定有效肿瘤新抗原的方法
WO2023180966A1 (en) Peptides for the preparation of vaccines against sars-cov-2